Muller Lorenz 4/A

What Happened

• Muller Lorenz, Chief Commercial Officer of Milestone Pharmaceuticals (MIST), was granted a derivative award on February 2, 2026 covering 204,000 shares. The reported acquisition price is $0.00 (derivative/award), and this filing amends an earlier Form 4 to correct the exercise price information.

Key Details

• Transaction date: 2026-02-02; filing date (amendment): 2026-02-05.
• Amount: 204,000 shares granted as a derivative award (reported acquisition price $0.00).
• Shares owned after transaction: not disclosed in this filing.
• Footnotes: F1 notes the initial filing misstated the exercise price (this amended Form 4 corrects that). F2: vesting — 1/4 of option vests on Feb 2, 2027, then 1/36 of the remaining shares vest each month thereafter, subject to continued service.
• No indication these shares were sold or immediately cashed out.

Context

• This is a compensation-related derivative grant (an option/award) rather than an open-market purchase or sale; such awards are common in executive pay and reflect compensation/retention rather than a direct buy/sell market signal. The amended filing corrects exercise-price details; consult future Form 4s for exercises, sales, or post-vesting ownership changes.